Reckitt Benckiser to sell its infant formula business in China for US$2.2 billion

Reckitt Benckiser

Reckitt Benckiser Group plc (LON:RKT) has announced that it has entered into a definitive agreement to sell its Infant Formula and Child Nutrition business in China to Primavera Capital Group for an implied enterprise value of US$2.2 billion.  Reckitt will retain a shareholding in IFCN China of 8% and anticipates net cash proceeds to be approximately US$1.3 billion.

The transaction follows a comprehensive strategic review of IFCN China announced in February 2021.  The transaction is structured as a sale of the entirety of IFCN China, including the manufacturing plants in Nijmegen, the Netherlands and Guangzhou, China.  It includes a royalty-free perpetual and exclusive license of the Mead Johnson and Enfa family of brands in China.  Following completion of the transaction, Reckitt will continue to own the Mead Johnson and Enfa family of brands globally and will operate those brands in the rest of the world. 

The transaction is subject to consultation with Reckitt’s works council in the Netherlands, which Reckitt will now initiate.  Reckitt will also engage with its other relevant employee unions in relation to the transaction.  Subject to the Netherlands works council consultation and the satisfaction of customary closing conditions, completion is expected in the second half of 2021.

Reckitt expects to incur cash tax costs of around £300 million and transaction and other costs of around £200 million.  The net proceeds will be used to reduce net debt and would have lowered the December 2020 net debt / adjusted EBITDA ratio by around 0.2x to 2.2x.

As at December 2020, IFCN net assets totalled £8.8 billion on a global basis.  Following the definitive agreement to sell IFCN China, Reckitt’s IFCN net assets have been separated geographically for accounting purposes; with £3.4 billion allocated to China and £5.4 billion allocated to North America and the rest of the world.  As a result of the sale, Reckitt expects to incur a net loss of around £2.5 billion principally relating to the re-measurement of goodwill and intangible assets for IFCN China.

Primavera Founder and Chairman Dr. Fred Hu said:

“We look forward to a strong collaboration with Reckitt, to continue to build on the heritage and strength of the Mead Johnson brand.  We have considerable experience investing and growing and expanding global brands in China.  We are excited to support the business in its next phase of growth, leveraging our resources and local leadership.”

Commenting on the sale, Reckitt Benckiser CEO Laxman Narasimhan said:

“Today’s announcement marks another step in our strategy to rejuvenate growth and create long term value.  As part of this journey, we are actively, and decisively, managing our portfolio. 

“After a thorough review of IFCN China, we have found an excellent home for the business under the ownership of Primavera.  As a result of this transaction, our Nutrition business going forward will have a better and more consistent growth and margin profile.  We are market leaders in infant nutrition in North America, ASEAN and Latin America, and we have a strong Vitamins, Minerals and Supplements portfolio which includes an exciting Adult Nutrition business.  This, combined with our focus on execution, brand building and productivity, our investment in R&D and innovation, and our expertise in eCommerce, gives us a solid foundation from which to grow.

“We remain committed to China with our Hygiene, Health and VMS portfolios.  We are excited about the opportunities to grow our brands and expand our business in the future.  China is Durex’s largest market and growing strongly and it is an important market for Dettol, Finish and our VMS brands with significant potential for future expansion. 

“Our portfolio is increasingly well-positioned to benefit from attractive fundamentals which, combined with our increased focus on operational execution, gives us confidence that we are taking the right steps to meet our medium-term targets.”

Share on:

Latest Company News

Reckitt Benckiser appoints Deborah Waterhouse and Gavin Patterson as non-executive directors

Reckitt has appointed Deborah Waterhouse and Gavin Patterson to its Board as non-executive directors, effective from 1 July 2026.

Reckitt hosting “Focus On: Digital Science” investor seminar today

Reckitt will host its latest “Focus On” investor seminar, highlighting how its digital and R&D teams use proprietary data, predictive science and generative AI to accelerate innovation and productivity. The event begins at 15:00 BST and will be led by Chief R&D Officer Angela Naef, alongside senior finance, technology and AI leaders.

Reckitt Benckiser reports Q1 2026 growth and keeps full-year outlook unchanged

Reckitt reported Q1 2026 like-for-like net revenue growth of 0.6% for the group and 1.3% for Core Reckitt, with strong emerging markets performance partly offset by weak seasonal OTC demand, softer Europe categories and disruption in the Middle East.

Reckitt Benckiser to host investor seminar on Emerging Markets strategy

Reckitt Benckiser Group will hold its latest 'Reckitt Focus On' investor seminar, with today's session centred on Emerging Markets.

Reckitt Benckiser posts 7% Q3 revenue growth

Reckitt Benckiser delivered a 7% rise in like-for-like group revenue for Q3 2025, supported by 6.7% growth in Core Reckitt and strong momentum in Emerging Markets.

Reckitt Benckiser reports 4.2% core revenue growth and upgraded 2025 outlook

Reckitt Benckiser delivered a strong H1 2025, with Core Reckitt like‑for‑like net revenues up 4.2% and Emerging Markets growth of 12.8%. Adjusted operating profit margin improved by 110 bps to 24.6%, supporting a 5% rise in the interim dividend and an upgrade to full‑year LFL net revenue guidance above 4% for Core Reckitt.

    Search